Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
bimagrumab
Description:
An investigational monoclonal antibody that blocks activin type II receptors and is studied as a treatment for muscle loss and metabolic conditions.
Related topics:
Muscle Physiology and Disorders (18%),
Nutrition and Health in Aging (18%),
Pharmacology and Obesity Treatment (17%),
Inflammatory Myopathies and Dermatomyositis (16%)
Wikidata ID:
wiki/Q15708291
OpenAlex ID:
keywords/bimagrumab
What is the pipeline for future medications for obesity?
2024
·
Eka Melson
, Uzma Ashraf
, et al.
·
International Journal of Obesity
·
409
PDF
Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial
2021
·
Steven B. Heymsfield
, Laura A. Coleman
, et al.
·
JAMA Network Open
·
374
PDF
An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
2013
·
Estelle Lach-Trifilieff
, Giulia C. Minetti
, et al.
·
Molecular and Cellular Biology
·
330
Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof‐of‐Concept Study
2017
·
Daniel Rooks
, Jens Praestgaard
, et al.
·
Journal of the American Geriatrics Society
·
273
Treatment of sporadic inclusion body myositis with bimagrumab
2014
·
Anthony A. Amato
, Kumaraswamy Sivakumar
, et al.
·
Neurology
·
217
PDF
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial
2020
·
Daniel Rooks
, Therese Swan
, et al.
·
JAMA Network Open
·
213
PDF
Muscle-bone interactions: From experimental models to the clinic? A critical update
2015
·
Michaël R. Laurent
, Vanessa Dubois
, et al.
·
Molecular and Cellular Endocrinology
·
163
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
2019
·
Michael G Hanna
, Umesh A Badrising
, et al.
·
The Lancet Neurology
·
161
PDF
The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation
2024
·
Konstantinos Stefanakis
, Michail Kokkorakis
, et al.
·
Metabolism
·
157
Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
2017
·
Frederic Morvan
, Jean-Michel Rondeau
, et al.
·
Proceedings of the National Academy of Sciences
·
157
PDF
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
2024
·
Elizabeth Nunn
, Natasha Jaiswal
, et al.
·
Molecular Metabolism
·
140
An update on peptide-based therapies for type 2 diabetes and obesity
2023
·
Clifford J. Bailey
, Peter R. Flatt
, et al.
·
Peptides
·
127
Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial
2018
·
Michael I. Polkey
, Jens Praestgaard
, et al.
·
American Journal of Respiratory and Critical Care Medicine
·
122
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
2026
·
Steven B. Heymsfield
, Louis J. Aronne
, et al.
·
Nature Medicine
·
102
Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy
2017
·
Daniel S. Rooks
, Didier Laurent
, et al.
·
Journal of Cachexia Sarcopenia and Muscle
·
101
PDF
Bimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
2017
·
Tania Garito
, Ronenn Roubenoff
, et al.
·
Diabetes Obesity and Metabolism
·
90
ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments
2016
·
Shinji Hatakeyama
, Serge Summermatter
, et al.
·
Skeletal Muscle
·
90
PDF
Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
2021
·
Donna H. Ryan
·
Journal of Obesity & Metabolic Syndrome
·
84
PDF
Therapeutic advances in sarcopenia management: From traditional interventions to personalized medicine
2025
·
Xiangliang Liu
, Xinqiao Chen
, et al.
·
Clinical Nutrition
·
78
Novel therapeutic options for cachexia and sarcopenia
2016
·
Alessio Molfino
, Maria Ida Amabile
, et al.
·
Expert Opinion on Biological Therapy
·
58
Effect of Bimagrumab on body composition: a systematic review and meta-analysis
2024
·
Mehmet Kanbay
, Dimitrie Siriopol
, et al.
·
Aging Clinical and Experimental Research
·
57
PDF
Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohort
2020
·
Daniel Rooks
, Olivier Petricoul
, et al.
·
Journal of Cachexia Sarcopenia and Muscle
·
57
PDF
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
2025
·
Donna H. Ryan
·
Reviews in Endocrine and Metabolic Disorders
·
51
PDF
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT
2021
·
Anthony A. Amato
, Michael G. Hanna
, et al.
·
Neurology
·
51
PDF
Emerging drugs affecting skeletal muscle function and mitochondrial biogenesis – Potential implications for sports drug testing programs
2016
·
Mario Thevis
, Wilhelm Schänzer
·
Rapid Communications in Mass Spectrometry
·
49
Show more works
View as search
Works count:
143
Citation count:
4,311
Year
Topic
Type